Insights & Updates in the Multidisciplinary Treatment of Metastatic Melanoma
August 19, 2019
August 19, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Society of Surgical Oncology (SSO) in partnership with The Academy for Continued Healthcare Learning.
This activity is partially supported by independent educational grants from Novartis Pharmaceuticals, Inc. and Array BioPharma.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is intended for surgical oncologists, medical oncologists, and other health care professionals who treat patients with metastatic melanoma.
To inform physicians on strategies for selecting adjuvant therapy in melanoma as well as use of systemic therapy in metastatic melanoma based on new treatment approvals of clinical interest, with practice-changing implications.
Upon completion of this activity, participants should be able to:
- Describe new options for systemic therapy for melanoma, specifically molecular targeted therapy and immunotherapy both in the adjuvant and metastatic setting
- Identify and manage the adverse events associated with targeted therapy and immunotherapy agents for metastatic melanoma
- Discuss the role of surgery and adjuvant therapy in the multidisciplinary treatment of metastatic melanoma
Jonathan Zager, MD
Director of Regional Therapies in Cutaneous Oncology and Sarcoma
Moffit Cancer Center
Nikhil I. Khushalani, MD
Vice Chair, Department of Cutaneous Oncology
Moffit Cancer Center
The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Society of Surgical Oncology designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The SSO has approved this activity for up to 0.5 self-assessment credit which meets the requirement of the self-assessment component of the American Board of Surgery (ABS) Continuous Certification Program.
In accordance with the ACCME’s Accreditation Criteria, the Society of Surgical Oncology must ensure that anyone in position to control the content of this educational activity has disclosed all financial relationships with a commercial interest. All educational planners, authors, reviewers, and other individuals in a position to control or influence the content of this activity were required to disclose all financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.
The ACCME also requires that the Society of Surgical Oncology resolve any reported conflict of interest and ensure the educational content of this activity is vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.
All identified conflicts of interests have been resolved.
Jonathan Zager, MD
- Consultant: Philogen, Castle Biosciences, Amgen
- Advisory Board: Array Biopharma, Merck
- Speaker Honorarium: Amgen, Array Biopharma
- Research: Amgen, Philogen, Provectus, Novartis, Delcath Systems, Castle Biosciences, Melagenix/NeraCare
- Grant: Delcath Systems
Nikhil I. Khushalani, MD
- Consultant: Bristol-Myers Squibb, AstraZeneca, EMD Serono, Regeneron, HUYA Bioscience Int'l, Genentech, Array BioPharma, Merck, Immunocore
- Research - (All to Institute): Bristol-Myers Squibb, Merck, Novartis, GlaxoSmithKline, Huya Bioscience Int'l, Amgen, Regeneron
- Stocks: Bellicum Pharamaceuticals, Mazor Robotics, TransEnterix, Amaric Corp
- Data Safety Monitoring Board: Astra-Zeneca
Planners, Reviewers, and Staff
R. Y. Declan Fleming, MD, CME Committee Reviewer: Consultant – Medtronic Corporation
Prejesh Philips, MD, CME Committee Reviewer: has disclosed no financial relationships.
Alanna Persaud, Program Manager; Kelley Gazer, Education Coordinator; Patti Stella, Education Director, Society of Surgical Oncology, have disclosed no financial relationships.
Vanessa Senatore, Program Director; Arman Nabatiyan, Scientific Director; Ritesh Kothari, Digital Strategy, The Academy for Continued Healthcare Learning, have disclosed no financial relationships.
Disclosure of Unlabeled Use
This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.
Requirements for Earning Credit and Method of Participation
This online activity consists of a pre-test, 2 interview segments, a self-assessment exam, and an evaluation. To receive AMA PRA Category 1 Credit™ and self-assessment credit, participants must watch both interviews, successfully complete the self-assessment exam, and achieve a minimum score of 75% on the exam. The self-assessment exam includes 4 multiple choice questions. Learners will be asked to read each question, select an answer, and review the section of the webinar where the answer is found. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a post activity evaluation. A certificate of credit will be available upon successful submission of the post-activity evaluation.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
The primary purpose of the Society of Surgical Oncology's enduring material is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.
Privacy and Confidentiality
Questions, please contact us at firstname.lastname@example.org.